Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 106.7b

Swedish Orphan Biovitrum Future Growth

Future criteria checks 3/6

Swedish Orphan Biovitrum is forecast to grow earnings and revenue by 19.8% and 9% per annum respectively. EPS is expected to grow by 20.4% per annum. Return on equity is forecast to be 12.8% in 3 years.

Key information

19.8%

Earnings growth rate

20.4%

EPS growth rate

Biotechs earnings growth44.4%
Revenue growth rate9.0%
Future return on equity12.8%
Analyst coverage

Good

Last updated13 Dec 2024

Recent future growth updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08
Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27
Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24
Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06
Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15
Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17
Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Earnings and Revenue Growth Forecasts

OM:SOBI - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202631,4666,4969,0909,83511
12/31/202528,0064,8687,3068,11911
12/31/202425,4663,5055,9506,05711
9/30/202425,4353,5143,2556,663N/A
6/30/202423,7102,1455,0566,716N/A
3/31/202423,1402,1422,3134,743N/A
12/31/202322,1232,409-4734,470N/A
9/30/202321,2702,7697435,291N/A
6/30/202320,1003,1251204,977N/A
3/31/202319,1043,1623374,915N/A
12/31/202218,7902,6383,0994,576N/A
9/30/202217,6962,4933,1454,804N/A
6/30/202217,4582,5163,3634,317N/A
3/31/202216,7932,5264,9795,415N/A
12/31/202115,5292,6795,1005,470N/A
9/30/202115,2142,9401,4054,066N/A
6/30/202114,4242,7443784,190N/A
3/31/202114,2832,7598194,739N/A
12/31/202015,2613,2451,0744,926N/A
9/30/202015,5703,1033,1015,185N/A
6/30/202015,5303,3675,7475,799N/A
3/31/202015,6223,5835,1765,132N/A
12/31/201914,2483,304-5,1713,634N/A
9/30/201911,9292,539-4,8683,195N/A
6/30/201911,3132,620-6,5262,912N/A
3/31/201910,4402,806-7,2332,201N/A
12/31/20189,1392,4181,5122,090N/A
9/30/20188,4432,1811,2171,810N/A
6/30/20187,7291,881N/A1,678N/A
3/31/20187,0791,462N/A1,287N/A
12/31/20176,5111,149N/A1,333N/A
9/30/20175,927865N/A1,103N/A
6/30/20175,497677N/A604N/A
3/31/20175,327703N/A431N/A
12/31/20165,204802N/A343N/A
9/30/20164,727716N/A329N/A
6/30/20164,341585N/A493N/A
3/31/20163,636291N/A573N/A
12/31/20153,22865N/A507N/A
9/30/20153,11959N/A547N/A
6/30/20153,000108N/A426N/A
3/31/20152,899136N/A268N/A
12/31/20142,607-268N/A234N/A
9/30/20142,513-263N/A185N/A
6/30/20142,364-373N/A86N/A
3/31/20142,221-410N/A189N/A
12/31/20132,177-93N/A185N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SOBI's forecast earnings growth (19.8% per year) is above the savings rate (1.2%).

Earnings vs Market: SOBI's earnings (19.8% per year) are forecast to grow faster than the Swedish market (14.6% per year).

High Growth Earnings: SOBI's earnings are forecast to grow, but not significantly.

Revenue vs Market: SOBI's revenue (9% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: SOBI's revenue (9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SOBI's Return on Equity is forecast to be low in 3 years time (12.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 20:35
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Rosie TurnerBarclays
Brian BalchinBarclays